N
PACB icon

Nuveen’s Pacific Biosciences PACB Stock Holding History

Nuveen’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.9M Buy
2,950,929
+2,102,710
+248% +$3.76M ﹤0.01% 1984
2025
Q4 		$1.59M Buy
848,219
+578,035
+214% +$1.11M ﹤0.01% 2392
2025
Q3 		$346K Hold
270,184
– – ﹤0.01% 3019
2025
Q2 		$335K Hold
270,184
– – ﹤0.01% 3008
2025
Q1 		$319K Hold
270,184
– – ﹤0.01% 3022
2024
Q4 		$494K Hold
270,184
– – ﹤0.01% 2989
2024
Q3 		$459K Hold
270,184
– – ﹤0.01% 3044
2024
Q2 		$370K Sell
270,184
-409,742
-60% -$827K ﹤0.01% 3090
2024
Q1 		$2.55M Buy
679,926
+14,121
+2% +$82.7K ﹤0.01% 2286
2023
Q4 		$6.53M Buy
665,805
+7,057
+1% +$57.7K ﹤0.01% 1826
2023
Q3 		$5.5M Sell
658,748
-4,281
-0.6% -$48.9K ﹤0.01% 1819
2023
Q2 		$8.82M Buy
663,029
+5,231
+0.8% +$63.6K ﹤0.01% 1592
2023
Q1 		$7.62M Sell
657,798
-47,309
-7% -$470K ﹤0.01% 1648
2022
Q4 		$5.77M Sell
705,107
-167,530
-19% -$1.44M ﹤0.01% 1829
2022
Q3 		$5.07M Sell
872,637
-10,278
-1% -$59K ﹤0.01% 1894
2022
Q2 		$3.9M Sell
882,915
-187,388
-18% -$1.14M ﹤0.01% 2109
2022
Q1 		$10.6M Sell
1,070,303
-102,415
-9% -$1.18M ﹤0.01% 1598
2021
Q4 		$24M Sell
1,172,718
-76,841
-6% -$1.85M 0.01% 1108
2021
Q3 		$36.8M Sell
1,249,559
-29,020
-2% -$860K 0.01% 852
2021
Q2 		$44.7M Buy
1,278,579
+160,159
+14% +$4.66M 0.01% 809
2021
Q1 		$37.3M Buy
1,118,420
+280,568
+33% +$9.82M 0.01% 894
2020
Q4 		$21.7M Buy
837,852
+175,450
+26% +$2.98M 0.01% 1207
2020
Q3 		$6.54M Buy
662,402
+101,446
+18% +$584K ﹤0.01% 1781
2020
Q2 		$1.94M Sell
560,956
-12,128
-2% -$41.3K ﹤0.01% 2352
2020
Q1 		$1.75M Buy
573,084
+19,593
+4% +$80.2K ﹤0.01% 2251
2019
Q4 		$2.85M Sell
553,491
-689
-0.1% -$3.5K ﹤0.01% 2269
2019
Q3 		$2.86M Buy
554,180
+12,336
+2% +$69K ﹤0.01% 2244
2019
Q2 		$3.28M Buy
+541,844
New +$3.8M ﹤0.01% 2206

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nuveen's PACB Position: Q1 2026 in Review

Nuveen increased its Pacific Biosciences (PACB) stake by 248% in Q1 2026, buying an estimated $3.76M and bringing the position to 2,950,929 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1984.

Nuveen first reported a position in PACB in Q2 2019 and has held it in 28 quarters since. The position peaked at $44.7M in Q2 2021. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Nuveen held 2,950,929 shares of Pacific Biosciences worth $3.9M as of Q1 2026.
  • Nuveen bought 2,102,710 Pacific Biosciences shares in Q1 2026, an estimated $3.76M.
  • Pacific Biosciences made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1984 holding.
  • Nuveen first reported a position in Pacific Biosciences in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Pacific Biosciences position peaked at $44.7M in Q2 2021.
  • 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.